Table 3.
Detailed between‐group comparisons of change of HRQL from baseline to 180 day follow‐up in patients admitted due to AHF and randomized to usual care versus intensive vasodilatation
| (A) EQ‐5D | All patients with EQ‐5D (n = 284) | Standard care (n = 134) | Intensive vasodilatation (n = 150) | P‐value* | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow‐up | Baseline | Follow‐up | Baseline | Follow‐up | |||
| MO | No problems | 109 (38) | 131 (46) | 53 (40) | 62 (46) | 56 (37) | 69 (46) | 0.360 |
| Some problems | 163 (57) | 148 (52) | 76 (57) | 70 (52) | 87 (58) | 78 (52) | ||
| Severe problems | 12 (4) | 5 (2) | 5 (4) | 2 (2) | 7 (5) | 3 (2) | ||
| SC | No problems | 198 (70) | 209 (74) | 94 (70) | 101 (75) | 104 (69) | 108 (72) | 0.443 |
| Some problems | 76 (27) | 65 (23) | 36 (27) | 28 (21) | 40 (27) | 37 (25) | ||
| Severe problems | 10 (4) | 10 (4) | 4 (3) | 5 (4) | 6 (4) | 5 (3) | ||
| UA | No problems | 105 (37) | 128 (49) | 49 (37) | 70 (52) | 56 (37) | 68 (45) | 0.435 |
| Some problems | 149 (53) | 126 (44) | 74 (55) | 57 (43) | 75 (50) | 69 (46) | ||
| Severe problems | 30 (11) | 20 (7) | 11 (8) | 7 (5) | 19 (13) | 13 (9) | ||
| PD | No | 116 (41) | 120 (42) | 58 (43) | 51 (38) | 58 (39) | 69 (46) | 0.019 |
| Some | 149 (53) | 151 (53) | 70 (52) | 76 (57) | 79 (53) | 75 (50) | ||
| Severe | 19 (7) | 13 (5) | 6 (5) | 7 (5) | 13 (9) | 6 (4) | ||
| AD | No | 189 (67) | 177 (62) | 86 (64) | 89 (66) | 103 (69) | 88 (59) | 0.039 |
| Some | 86 (30) | 98 (35) | 44 (33) | 41 31) | 42 (28) | 57 (38) | ||
| Severe | 9 (3) | 9 (3) | 4 (3) | 4 (3) | 5 (3) | 5(3) | ||
| (B) KCCQ | All patients with KCCQ (n = 198) | Standard care (n = 94) | Intensive vasodilatation (n = 104) | P‐value* | ||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow‐up | Baseline | Follow‐up | Baseline | Follow‐up | |||
| Symptom frequency | 37.5 [25.0, 59.9] | 78.5 [52.1, 91.7] | 35.4 [25.0, 57.8] | 74.0 [52.1, 91.7] | 39.6 [26.6, 60.4] | 79.2 [53.6, 94.8] | 0.459 | |
| Symptom burden | 50.0 [33.3, 66.7] | 83.3 [52.1, 91.7] | 50.0 [25.0, 58.3] | 83.3 [50.0, 100.0] | 50.0 [33.3, 75.0] | 83.3 [66.7, 91.7] | 0.382 | |
| Physical limitation | 54.2 [33.8, 68.2] | 70.8 [50.0, 87.5] | 54.2 [37.5, 66.7] | 70.8 [42.7, 87.5] | 54.2 [33.3, 75.0] | 70.8 [50.0, 87.5] | 0.457 | |
| Social limitation | 41.7 [25.0, 68.8] | 75.0 [37.5, 90.6] | 43.8 [25.0, 62.5] | 75.0 [43.8, 98.4] | 41.7 [18.8, 75.0] | 75.0 [31.2, 87.5] | 0.216 | |
| Self‐efficacy | 62.5 [50.0, 75.0] | 75.0 [62.5, 87.5] | 62.5 [50.0, 75.0] | 75.0 [62.5, 100.0] | 62.5 [43.8, 87.5] | 75.0 [62.5, 87.5] | 0.114 | |
| Quality of life | 41.7 [25.0, 58.3] | 75.0 [50.0, 90.6] | 41.7 [27.1, 58.3] | 75.0 [50.0, 91.7] | 41.7 [25.0, 60.4] | 75.0 [50.0, 84.4] | 0.429 | |
| KCCQ‐OSS | 43.5 [30.3, 62.8] | 71.8 [49.5, 87.0] | 42.6 [31.5, 57.9] | 70.3 [50.2, 89.5] | 43.8 [27.8, 64.9] | 72.8 [49.5, 84.1] | 0.378 | |
AHF, acute heart failure; AD = anxiety/depression; HRQL, health‐related quality of life; KCCQ‐OSS, Kansas City Cardiomyopathy Questionnaire overall summary score; MO, mobility; PD, pain/discomfort; SC, self‐care; UA, usual activities.
*
P‐value for comparison of change between standard care and intensive vasodilatation.